Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Biosimilars
 More »

THIS KEYWORD IS SPONSORED BY:

  • World Biosimilars Congress
    Geneva SWITZERLAND www.terrapinn.com/2013/biosimilars-congress
    11-12-2013
  • Biosimilars & Biobetters
    London UNITED KINGDOM http://www.smi-online.co.uk/goto/2013biosimilars-biobetters19.asp
    10-1-2013
  • Samsung Biologics, BMS in Manufacturing Partnership
    relatively young company, this isn't Samsung Biologics' first major deal: In December 2011, the firm established a joint venture with Biogen Idec to develop and market biosimilars. ...
    7-29-2013
  • Pfizer Splitting Commercial Operations Three Ways, Inks Supply...
    patent-protected products that are expected to lose exclusivity through 2015 in most major markets, biosimilars, and current and future established products collaborations." ...
    7-29-2013
  • Biosimilar Marriage Ends in Divorce for Teva, Lonza
    The companies hoped to bring numerous biosimilars to market and "secure a leading position in the emerging biosimilars market," they said in launching the joint venture in 2009. ...
    7-25-2013
  • Mitsubishi Tanabe Buys Medicago for $357M
    development into other areas such as biosimilars and biodefense products where the ... work on rapid vaccines, expanding into biosimilars, biodefense. Mitsubishi Tanabe Buys ...
    7-12-2013
  • Top 15 Vaccines of 2012
    These top-sellers could be the booster shots the industry needs. You've seen GEN's list of biosimilars to watch ; now, following is a list of 15 vaccines, ranked by sales and ...
    7-2-2013
  • Latest Biosimilar Guidance Raises More Questions
    More than a year after issuing three draft guidances on biosimilars, however, FDA has been ... for developing future policies on biosimilars, including guidance on clinical ...
    6-21-2013
  • Cancer's Bitter Medicine
    ... biologics, for which the regulatory pathway to biogenerics or biosimilars is still in its infancy. Once biosimilars become commonplace for biologics going off patent, we will see ...
    6-15-2013
  • Merck, BMS Immunotherapy Data Whets Clinical Oncology Appetite...
    ... including its axitinib, bosutinib, crizotinib, dacomitinib, inotuzumab ozogamicin, palbociclib, and sunitinib, plus a handful of early-development compounds and biosimilars. ...
    6-3-2013
  • Flexibility in Biopharmaceutical Manufacturing Capacity
    ... products will account for 57% of the global biosimilars market. The cost and complexity of developing and manufacturing biosimilars also suggests that, realistically, product ...
    5-28-2013
  • Cancer's Bitter Medicine
    ... biologics, for which the regulatory pathway to biogenerics or biosimilars is still in its infancy. Once biosimilars become commonplace for biologics going off patent, we will see ...
    5-21-2013
  • Heightened Characterization of Therapeutic mAbs Using a Novel...
    LC-MS analysis How this enzyme can be used for rapid comparability studies of biosimilars vs. innovator compounds How these enzyme systems can be used to screen production ...
    5-15-2013
  • Improving Proteomics Approaches
    ... trend toward biotherapeutics and the need for rapid analysis and characterization of putative products. "Related are biotech patent expirations and the development of biosimilars." ...
    5-15-2013
  • Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
    for the Chinese market four biosimilars being developed by U.S.-based ... partnership for launching the biosimilars in more than 30 developed countries, ...
    5-8-2013

  • Journal Articles

  • The Emergence of Biosimilar Insulin Preparations-A Cause for...
    David Owens, Andrea Schmidt, Wolfgang Landgraf, Reinhard G. Bretzel, Martin K Kuhlmann
    Diabetes Technology & Therapeutics
    are, or shortly will be, off-patent, thereby becoming the focus of pharmaceutical companies interested in attempting to manufacture "copies" commonly described as biosimilars. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll